WNWilliam A. Nyberg

William A. Nyberg

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


William A. Nyberg has a total of 160 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Disruption of the CRL5 Ubiquitin Ligase Complex Enhances Engineered T-cell Persistence under Chronic Tumor Antigen Exposure

    by Stefanie Bachl, Carter Ching, Alexis Talbot, Antoine Forget, Nupura Kale, Clara Kochendoerfer, William A. Nyberg, Zhongmei Li, Peixin Amy Chen, Patrick H. Kennedy, et al.

    Engineered T-cell therapies are limited by progressive dysfunction under chronic tumor antigen exposure, and genetic perturbation of negative regulators has emerged as a promising strategy to sustain effector activity. We reanalyzed a genome-wide CRISPR knockout (KO) screen in primary human T cells under repetitive tumor stimulation; protein–protein interaction mapping revealed seven members of the cullin–RING ligase 5 (CRL5) complex as an enriched hit cluster. KO of any of these members [cullin-5 (CUL5), ARIH2, RNF7, UBE2F, UBE2L3, CISH, and DCUN1D3] enhanced tumor serial killing, and CUL5, the complex scaffold, emerged as the strongest target. CUL5 KO T cells exhibited sustained cytotoxicity, elevated effector cytokine production, and fewer exhaustion marker–positive cells while retaining antigen specificity and cytokine dependence. Quantitative ubiquitylation proteomics in resting and acutely and chronically stimulated T cells mapped CRL5-dependent candidate substrates beyond the canonical JAK/STAT axis, including nutrient transporters, receptor trafficking proteins, and T-cell receptor (TCR) signaling components. The benefit of CUL5 KO extended across chimeric antigen receptor (CAR) targeting CD19, B-cell maturation antigen (BCMA), and human epidermal growth factor receptor 2 (HER2) with different costimulatory domains and to 1XX-modified CAR and human leukocyte antigen–independent TCR architectures. Combining CUL5 ablation with a tumor-induced IL2 circuit produced tumor control across nine rounds of repetitive stimulation, whereas either modification alone eventually failed. In vivo, CUL5 KO BCMA CAR T cells were enriched in the bone marrow following repeated tumor rechallenge and exhibited enhanced ex vivo cytotoxicity after nearly 90 days in tumor-bearing mice. These findings position CUL5 perturbation as a strategy to improve T-cell persistence and the efficacy of adoptive cell therapies, potentially with engineered cytokine support. Significance: Knockout of CLR5 complex members, especially CUL5, attenuates T-cell exhaustion during prolonged tumor exposure, enabling CAR- and TCR-engineered T cells to sustain cytotoxicity during repeated tumor challenge. See related commentary by Hanina and Maus, p. XX . See related article by Saco et al., p. XX .

  • Open Access

    One-step generation of T-cell receptor knock-in mice in the TCRβ locus

    by Jana Bilanovic, Juliana Bortolatto, Susu Duan, Valgerdur Bjørnsdottir, A Katharina Teetz, Alexandra Thoms, Julian Fischbach, Fabian Schmidt, William A Nyberg, Harald Hartweger, et al.

    Transgenic mouse models expressing predefined T-cell receptors (TCRs) have been instrumental in advancing our understanding of T-cell biology. However, these traditional models rely on random genomic insertion of large constructs, require labor-intensive embryo manipulation, and frequently result in aberrant TCR expression and phenotypes. These limitations render traditional models insufficient to meet the mounting demands for rapid and precise model systems to evaluate TCR specificities. In this study, we developed a streamlined method that uses adeno-associated virus (AAV) and CRISPR/Cas9-mediated genome editing to precisely integrate pre-rearranged TCRα/β sequences into the mouse TCRβ ( Trb ) locus, enabling the rapid generation of TCR knock-in mice with physiological TCR expression and functional T-cell differentiation upon antigenic challenge. This approach bypasses the need for screening multiple founders for faithful TCR expression, enhancing the versatility and utility of monoclonal TCR mice in basic immunology and preclinical research, such as in the fields of cancer immunotherapy and vaccine development.

  • Local gene editing of fibroblasts in tumors reveals a new cancer-associated fibroblast state

    by Nicholas F. Kuhn, Itzia Zaleta-Linares, Kenneth H. Hu, Tristan Courau, Brittany Davidson, Tammie Tam, Chih-Wei Chu, Maxime J. Kinet, Michael D. Rosenblum, Alexis J. Combes, et al.

    Fibroblasts play critical roles in regulating cellular relationships during tissue homeostasis, immunity, and tumor biology at multiple sites. However, tools to perturb fibroblasts at just one site in vivo are limited, restricting our understanding of how these cellular relationships act locally. We optimized local gene editing of fibroblasts in mouse tumor models to investigate how fibroblast perturbations affect the tumor microenvironment (TME). By knocking out receptors Osmr, Tgfbr2, or Il1r1 on cancer-associated fibroblasts (CAFs), we uncover that TGFBR2 signaling loss induces the emergence of a new Col18a1hi CAF cell state that is associated with worse survival in pancreatic cancer patients. Combinatorial gene KOs in CAFs reveals a circuit where these Col18a1hi CAFs reshape the TME by recruiting Siglec-Fhi neutrophils via Cxcl5 expression, and where this Col18a1hi CAF cell state is dependent on TNFR1 and canonical Wnt signaling. Together, a fast, affordable, and modular engineering method is demonstrated, allowing discovery of modified fibroblast identities and local intercellular relationships in the TME.


  • Top Cited Papers
    Open Access

    In vivo site-specific engineering to reprogram T cells

    by William A. Nyberg, Pierre-Louis Bernard, Wayne Ngo, Charlotte H. Wang, Jonathan Ark, Allison Rothrock, Gina M. Borgo, Gabriella R. Kimmerly, Jae Hyung Jung, Vincent Allain, et al.

    Engineered T cells, reprogrammed to express chimeric antigen receptors (CAR) or T cell receptors (TCR), have transformed cancer treatment and are being explored as therapeutics for autoimmune and infectious diseases. Enhancing T cell function through genome editing, either by disrupting endogenous genes or precisely inserting DNA payloads, has shown considerable promise 1 . However, the ex vivo manufacturing process is lengthy and costly, limiting accessibility of these therapies. In vivo generation of CAR T cells could overcome these barriers, but current methods rely either on transient expression with limited durability, or on random integration of DNA payloads that lack specificity. Here we demonstrate that stable and cell-specific transgene expression can be achieved through in vivo site-specific integration of large DNA payloads. We developed a two-vector system to deliver CRISPR–Cas9 ribonucleoproteins and a DNA donor template, using enveloped delivery vehicles and adeno-associated viruses, respectively. We optimized both vectors for T cell-specific delivery and gene-targeting efficiency. By integrating a CAR transgene into a T cell-specific locus, we generate therapeutic levels of CAR T cells in vivo in humanized mouse models of B cell aplasia, and haematological and solid malignancies. These findings offer a pathway to more efficient, precise and widely accessible T cell therapies.


  • Open Access

    One-step generation of TCR knock-in mice targeted to the TCRβ locus results in functional mature T lymphocytes

    by Jana Bilanovic, Juliana Bortolatto, Susu Duan, Valgerdur Bjørnsdottir, A. Katharina Teetz, Alexandra Thoms, Julian Fishbach, Fabian Schmidt, William Nyberg, Harald Hartweger, et al.

    Transgenic mouse models expressing predefined T cell receptors (TCRs) have been instrumental in advancing our understanding of T cell biology. However, these traditional models rely on random genomic insertion of large constructs, require labor-intensive embryo manipulation, and frequently result in aberrant TCR expression and phenotypes. These limitations render TCR transgenic models insufficient to meet the mounting demands for rapid and precise model systems to evaluate TCR specificities. To address these challenges, we developed a streamlined method that combines Adeno-Associated Virus (AAV), coupled with CRISPR/Cas9 genome editing to precisely integrate pre-rearranged TCRα/β sequences into the mouse Trb locus, enabling the rapid generation of first-of-its-kind TCR knock-in mice with physiological TCR expression and functional T cell differentiation. This approach bypasses the need for technically advanced embryo manipulation and enables rapid generation of models through a universally optimized AAV vector system, significantly enhancing the versatility and utility of monoclonal TCR mice in basic immunology and preclinical research such as cancer immunotherapy and vaccine development, providing a transformative resource to accelerate discovery and translation across disciplines.

  • Open Access

    Site-specific genome engineering of primary human natural killer cells for programmable anti-tumor function

    by Vincent Allain, Allison G. Rothrock, Pierre-Louis Bernard, William A. Nyberg, Alexis Talbot, Joseph J. Muldoon, Jing-Yi Chung, Angela To, Christopher R. Chang, Gabriella R. Kimmerly, et al.

    Natural killer (NK) cells are emerging as a promising platform for engineered adoptive cell therapies. However, gene editing in NK cells remains challenging, and more effective strategies are needed. Here, we established a robust, feeder-free, and modular workflow for genome engineering in primary human NK cells, combining CRISPR/Cas9 with AAV6-mediated transgene delivery. Efficient site-specific transgene integration was achieved at various loci and can be coupled with concurrent disruption of the target locus in a single editing step. Furthermore, transgene expression was tunable according to the integration site and promoter. We applied this strategy to target a chimeric antigen receptor (CAR) transgene to a panel of inhibitory NK receptor loci, establishing a synergistic approach to enhance anti-tumor activity and facilitate the reliable comparison of CAR variants without expression bias. We identified TIGIT as an ideal locus that supports strong CAR expression and anti-tumor function. This genome engineering framework, which leverages multiple, complementary and precisely controlled genetic edits, can support the rational design of future NK-cell therapies tailored to overcome cell-intrinsic limitations and tumor-specific barriers.

  • Open Access

    SEED-Selection enables high-efficiency enrichment of primary T cells edited at multiple loci

    by Christopher R. Chang, Vivasvan S. Vykunta, Jae Hyun J. Lee, Ke Li, Clara Kochendoerfer, Joseph J. Muldoon, Charlotte H. Wang, Thomas Mazumder, Yang Sun, Daniel B. Goodman, et al.

    Engineering T cell specificity and function at multiple loci can generate more effective cellular therapies, but current manufacturing methods produce heterogenous mixtures of partially engineered cells. Here we develop a one-step process to enrich unlabeled cells containing knock-ins at multiple target loci using a family of repair templates named synthetic exon expression disruptors (SEEDs). SEEDs associate transgene integration with the disruption of a paired target endogenous surface protein while preserving target expression in nonmodified and partially edited cells to enable their removal (SEED-Selection). We design SEEDs to modify three critical loci encoding T cell specificity, coreceptor expression and major histocompatibility complex expression. The results demonstrate up to 98% purity after selection for individual modifications and up to 90% purity for six simultaneous edits (three knock-ins and three knockouts). This method is compatible with existing clinical manufacturing workflows and can be readily adapted to other loci to facilitate production of complex gene-edited cell therapies.


  • Open Access

    Discovery of a Linked Constellation of Gene Expression Revealed by Local Editing of Fibroblasts in Tumors

    by Nicholas F. Kuhn, Itzia Zaleta-Linares, Kenneth H. Hu, Tristan Courau, Brittany Davidson, Tammie Tam, Alexis J. Combes, William A. Nyberg, Justin Eyquem, Matthew F. Krummel

    Fibroblasts play critical roles in regulating cellular relationships during tissue homeostasis, immunity, and tumor biology at multiple sites. However, tools to perturb fibroblasts at just one site in vivo are limited, restricting our understanding of how these cellular relationships develop on a local level. We optimized local gene editing of fibroblasts in multiple mouse tumor models to investigate how locally restricted fibroblast perturbations affect the cellular tumor microenvironment (TME). By knocking out surface receptors Osmr, Tgfbr2, or Il1r1 on cancer-associated fibroblasts (CAFs), we uncover that TGFBR2 signaling loss uniquely induces the emergence of a Col18a1 hi CAF cell state that is distinct from previously described fibroblast states and is associated with worse survival in human PDAC patients. Further application of a local as well as combinatorial gene knockout technology in CAFs reveals a circuit in which these Col18a1 hi CAFs reshape the TME by recruiting Siglec-F hi neutrophils via Cxcl5 expression; and that the Col18a1 hi CAF cell state is further dependent on TNFR1 and canonical Wnt signaling. Together, a fast, affordable, and modular engineering method is demonstrated, allowing discovery of a modified fibroblast identify, as well as the network details of a local inter-cellular circuitry in a tumor. Graphical

  • Open Access

    Scalable intracellular delivery via microfluidic vortex shedding enhances the function of chimeric antigen receptor T-cells

    by Brandon J. Sytsma, Vincent Allain, Struan Bourke, Fairuz Faizee, Mohsen Fathi, Rebecca Berdeaux, Leonardo M.R. Ferreira, W. Jared Brewer, Lian Li, Fong L. Pan, et al.

    Adoptive chimeric antigen receptor T-cell (CAR-T) therapy is transformative and approved for hematologic malignancies. It is also being developed for the treatment of solid tumors, autoimmune disorders, heart disease, and aging. Despite unprecedented clinical outcomes, CAR-T and other engineered cell therapies face a variety of manufacturing and safety challenges. Traditional methods, such as lentivirus transduction and electroporation, result in random integration or cause significant cellular damage, which can limit the safety and efficacy of engineered cell therapies. We present hydroporation as a gentle and effective alternative for intracellular delivery. Hydroporation resulted in 1.7- to 2-fold higher CAR-T yields compared to electroporation with superior cell viability and recovery. Hydroporated cells exhibited rapid proliferation, robust target cell lysis, and increased pro-inflammatory and regulatory cytokine secretion in addition to improved CAR-T yield by day 5 post-transfection. We demonstrate that scaled-up hydroporation can process 5 × 10 8 cells in less than 10 s, showcasing the platform as a viable solution for high-yield CAR-T manufacturing with the potential for improved therapeutic outcomes.


  • Open Access

    Ultra-high efficiency T cell reprogramming at multiple loci with SEED-Selection

    by Christopher R. Chang, Vivasvan S. Vykunta, Daniel B. Goodman, Joseph J. Muldoon, William A. Nyberg, Chang Liu, Vincent Allain, Allison Rothrock, Charlotte H. Wang, Alexander Marson, et al.

    Multiplexed reprogramming of T cell specificity and function can generate powerful next-generation cellular therapies. However, current manufacturing methods produce heterogenous mixtures of partially engineered cells. Here, we develop a one-step process to enrich for unlabeled cells with knock-ins at multiple target loci using a family of repair templates named S ynthetic E xon/ E xpression Disruptors (SEEDs). SEED engineering associates transgene integration with the disruption of a paired endogenous surface protein, allowing non-modified and partially edited cells to be immunomagnetically depleted (SEED-Selection). We design SEEDs to fully reprogram three critical loci encoding T cell specificity, co-receptor expression, and MHC expression, with up to 98% purity after selection for individual modifications and up to 90% purity for six simultaneous edits (three knock-ins and three knockouts). These methods are simple, compatible with existing clinical manufacturing workflows, and can be readily adapted to other loci to facilitate production of complex gene-edited cell therapies.